Treatment of high-risk neuroblastoma: National protocol results of the Turkish Pediatric Oncology Group
| Autor: | Ferhan Akici, Emre Çeçen, Ali Varan, Ayhan Dagdemir, Dilek Ince, Haldun Öniz, Nur Olgun, Inci Ergurhan Ilhan, Elif Güler, Emel Ünal, Mustafa Buyukavci, Sema Vural, Volkan Hazar, Hilmi Apak, Betül Sevinir, Nilgun Kurucu, Sema Anak, Canan Vergin, Cengiz Canpolat, Rejin Kebudi, Ceyda Karadeniz, Serap Aksoylar |
|---|---|
| Přispěvatelé: | OMÜ, Ege Üniversitesi, Çocuk Sağlığı ve Hastalıkları |
| Jazyk: | angličtina |
| Rok vydání: | 2017 |
| Předmět: |
Oncology
Adult Male medicine.medical_specialty Autologous Stem Cell Rescue Transplantation Conditioning Adolescent Turkey medicine.medical_treatment lcsh:RC254-282 03 medical and health sciences Neuroblastoma Young Adult 0302 clinical medicine Clinical Protocols Internal medicine Medicine Humans Radiology Nuclear Medicine and imaging Young adult Child high-risk neuroblastoma Response rate (survey) Chemotherapy treatment business.industry Infant Newborn Induction chemotherapy Infant Multimodal therapy General Medicine medicine.disease lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens Surgery Autologous stem cell rescue 030220 oncology & carcinogenesis Child Preschool Female business 030217 neurology & neurosurgery Stem Cell Transplantation |
| Zdroj: | Journal of Cancer Research and Therapeutics, Vol 13, Iss 2, Pp 284-290 (2017) |
| Popis: | WOS: 000404741400022 PubMed ID: 28643749 Background: The national protocol aimed to improve the outcome of the high risk neuroblastoma patients by high-dose chemotherapy and stem cell rescue with intensive multimodal therapy. Materials and Methods: After the 6 induction chemotherapy cycles, patients without disease progression were nonrandomly (by physicians' and/or parent's choices) allocated into two treatment arms, which were designed to continue the conventional chemotherapy (CCT), or myeloablative therapy with autologous stem cell rescue (ASCR). Results: Fifty-six percent (272 patients) of patients was evaluated as high risk. Response rate to induction chemotherapy was 71%. Overall event-free survival (EFS) and overall survival (OS) at 5 years were 28% and 36%, respectively. "As treated" analysis documented postinduction EFS of 41% in CCT arm (n = 138) and 29% in ASCR group (n = 47) (P = 0.042); whereas, OS was 45% and 39%, respectively (P = 0.05). Thirty-one patients (11%) died of treatment-related complications. Conclusion: Survival rates of high-risk neuroblastoma have improved in Turkey. Myeloablative chemotherapy with ASCR has not augmented the therapeutic end point in our country's circumstances. The adequate supportive care and the higher patients' compliance are attained, the better survival rates might be obtained in high-risk neuroblastoma patients received myeloablative chemotherapy and ASCR. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|